Project Summary/Abstract Johns Hopkins has been an academic member institution of cooperative groups since the founding of this national oncology research program in 1955. Over the decades, our faculty have provided strong clinical and laboratory scientific leadership, and administrative leadership to the cooperative groups. Our primary goal for this grant is to provide scientific leadership for the development and conduct of NCTN clinical trials. The majority of our contributions and our longest association remains with ECOG-ACRIN and secondly with NRG. To promote continuity, executive committee members for the NCTN LAPS at Johns Hopkins will mentor early career investigators in NCTN Network Group and NCI initiatives. Johns Hopkins is committed to providing robust accruals annually to NCTN studies. This will be accomplished by efficiently activating studies across Hopkins’ institutions and satellite facilities and thereby offering NCTN clinical trials to our catchment area. In addition to accruals, Johns Hopkins will conduct quality research through timely activation of new studies, regulatory compliance, and timely and accurate data submissions. Quality assurance activities towards this aim will be overseen by the Grant Program Manager for the NCTN LAPS at Johns Hopkins. These goals align with the mission of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC). The Center has achieved excellence through research across the spectrum of cancer care using a multidisciplinary approach. With support from the NCI’s Cancer Center Support Grant, program projects, such as R01 and SPORE grants and the Early Therapeutic Clinical Trials Network (ETCTN) for early phase clinical trials, SKCCC investigators integrally collaborate and contribute to the NCI’s mission and ultimately bring clinical trials to the NCTN program.